Literature DB >> 25277213

Suggested statistical reappraisal of data from comparative study of febuxostat and allopurinol in chronic kidney disease.

Alan Zelicoff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25277213     DOI： 10.1007/s10067-014-2788-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  3 in total

1.  Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.

Authors:  Yugo Shibagaki; Iwao Ohno; Tatsuo Hosoya; Kenjiro Kimura
Journal:  Hypertens Res       Date:  2014-06-19       Impact factor: 3.872

2.  Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.

Authors:  Yuki Tsuruta; Toshio Mochizuki; Takahito Moriyama; Mitsuyo Itabashi; Takashi Takei; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Rheumatol       Date:  2014-07-22       Impact factor: 2.980

3.  The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

Authors:  Tatsuo Hosoya; Kenjiro Kimura; Sadayoshi Itoh; Masaaki Inaba; Shunya Uchida; Yasuhiko Tomino; Hirofumi Makino; Seiichi Matsuo; Tetsuya Yamamoto; Iwao Ohno; Yugo Shibagaki; Satoshi Iimuro; Naohiko Imai; Masanari Kuwabara; Hiroshi Hayakawa
Journal:  Trials       Date:  2014-01-16       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.